Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Moderna Q3 2026 Results: Turns Profitable, Net Income $162M

Moderna reported a net income of $162 million for the third quarter of 2026, a significant improvement from a $200 million loss in the prior year, driven by increased net product sales of $1.27 billion. However, for the nine months ended September 30, 2026, the company recorded a net loss of $1.96 billion and significantly increased its debt profile through the issuance of $3.0 billion in convertible notes.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue1,313.01,016.0
Profit before tax171.0-187.0
Net income162.0-200.0
EPS (diluted, $ a share)$0.38$-0.51

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+29.2%
Operating margin9.9%
Source

10-Q filed with the SEC, NASDAQ: MRNA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Moderna, Inc.: key numbers

Share price
$215.27Close, Nov 16
Market cap
$87.1B
Shares outstanding
404.62MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Moderna, Inc.

All →
6:33 PM ET 8-K
Loan & Debt

Moderna $900M Debt Financing with Ares Capital Corporation

Moderna entered into an amendment to its existing Credit and Guaranty Agreement with Ares Capital Corporation, reducing interest rate margins by 0.75 percentage points and extending the maturity date to November 24, 2031. The amendment also extends the availability period for $900 million in delayed draw term loan commitments through November 2029.

Value
$900M
Counterparty
Ares Capital Corporation
Term
through Nov 2031
4:02 PM ET 8-K
Leadership Change

Moderna Leadership Change

Moderna's Chief Legal Officer, Shannon Thyme Klinger, will retire from the company effective March 31, 2027. Under a transitional services agreement, she will receive $1.63 million in severance plus potential performance bonuses of up to $8 million tied to the outcomes of ongoing litigation with Arbutus, Genevant, Pfizer, and BioNTech.

6:48 AM ET 8-K
Financial Results

Moderna Financial Results

Moderna reported Q3 2026 revenue of $1.3 billion, a 29% increase year-over-year, and achieved GAAP net income of $162 million. The company raised its full-year 2026 revenue growth guidance to 15%–25% and highlighted the U.S. FDA approval of mFLUSIVA, its fifth approved product globally.

Term
Q3 2026

“We delivered 29% revenue growth in the third quarter, alongside the U.S. approval of mFLUSIVA, our fifth approved product globally, and positive Phase 3 results for intismeran in melanoma.”

Stéphane Bancel, Chief Executive Officer of Moderna

“Building on this momentum, we increased our full-year revenue growth outlook to 15%-25%, while continuing to reduce costs and strengthen our balance sheet. Looking ahead, we anticipate additional intismeran readouts, pivotal data in propionic acidemia and further regulatory approvals as we advance our pipeline and build a more diversified company.”

Stéphane Bancel, Chief Executive Officer of Moderna
4:09 PM ET Form 4
Insider Selling

Moderna President Stephen Hoge Sells $17M of Stock

Stephen Hoge, President, sold 78,369 shares of Moderna, Inc. at $213.47 to $220.72 a share (average $217.10) in 3 transactions, worth $17M in total between Oct 14, 2026 and Oct 15, 2026. Shares held after the trade: 1,636,565 (-2.3%).

Value
$17M
Shares
78,369
Average price
$217.10
Role
President
Holding change
-2.3%
Trade date
Oct 14, 2026 to Oct 15, 2026
7:15 AM ET 8-K
Executive Compensation

Moderna Executive Compensation

Moderna appointed Juan Andres as its new Chief Operating Officer, effective October 5, 2026, while announcing the retirement of Jerh Collins, Ph.D. Mr. Andres will receive an annual base salary of $800,000, a target bonus of 90%, and a new hire equity award valued at $5 million. The leadership change comes as the company expands its oncology portfolio and scales its global manufacturing network.

Counterparty
Juan Andres
4:49 PM ET Form 4
Insider Selling

Moderna President Stephen Hoge Sells $11.7M of Stock

Stephen Hoge, President, sold 80,575 shares of Moderna, Inc. at $144.13 to $146.07 a share (average $145.10) in 2 transactions, worth $11.7M in total between Sep 14, 2026 and Sep 15, 2026. Shares held after the trade: 1,562,029 (-2.5%).

Value
$11.7M
Shares
80,575
Average price
$145.10
Role
President
Holding change
-2.5%
Trade date
Sep 14, 2026 to Sep 15, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.